|
ALZN Alzamend Neuro Inc 1677077 |
| Income Statement |
|
Net Income
|
2026-07-31
|
$-3,027,002.00 |
| Balance Sheet |
|
Current Assets
|
$8,254,880.00 |
|
Assets
|
$8,542,061.00 |
|
Current Liabilities
|
$3,826,457.00 |
|
Liabilities
|
$2,739,381.00 |
|
Equity
|
$5,802,680.00 |
|
Shares Out
|
4825723.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-1,138,517.00 |
|
Investing Cash Flow
|
$-300,000.00 |
| Market Analysis |
Market Cap
|
$7,865,928.49 |
|
Price
|
$1.63 |
|
BVPS
|
1.20 |
|
PB
|
1.36 |
|
EPS
|
-0.68 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-09-01 09:33:03 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-09-14 10:01:53 |
|
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view ALZN documents filed with the SEC.
ALZN Filings
Clear
